The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Marketing
  • Entertainment
  • Event

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • The Hue Society Expands Roster for the 2026 Wine and Culture Fest
  • Exeter Smiles Encourages Families to Start Teen Braces This Summer
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • World Cup Crowds Are a Stress Test for America's Restrooms
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
  • Los Angeles' Best Food: Food Journal Magazine Examines the Trends Shaping the City's Dining Scene
  • Landmark Construction Expands Glass, Glazing, and Commercial Remodeling Services Across Los Angeles County and Surrounding Areas

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Michigan's Plane Crash Data Points Away from Big Airports
  • 2iG Solutions Launches MGA Insight, Bringing AI-Powered Business Intelligence to Managing General Agents
  • A Better Way to Find a Real Estate Agent Is Coming Soon
  • Talentica Software Earns a Place Among India's Top 100 Great Mid-size Workplaces 2026
  • 4-Week Search for 2 True "Philly Girls" Starts July 8th 2026
  • Socialhose Launches TikTok Investigator, a Platform for Investigating TikTok Live
  • David Pedrol named Managing Director in Indonesia
  • AutomationIQ Launches to Bring Enterprise-Grade AI Automation to Local and Mid-Market Businesses
  • Texas Hospitals & Their Patients Describe Two Very Different Healthcare Systems, New Social Knowing
  • DEPIN Studios Sees Surge in Demand After AI Gaming Launch
  • Discard Junk Removal Named #1 Junk Removal Company in Sacramento Out of 189 Businesses Evaluated
  • J&J Exterminating Mourns the Passing of Founder Bobby John Sr
  • Delirious Comedy Club Transforms Into Las Vegas' Newest Live Comedy Studio With Weekly Delirious TV Tapings
  • BitTitan Advances MigrationWiz with New Capabilities, Platform Enhancements, and Product Leadership Update
  • Sara Abbas Receives "Eniochos" Charioteer Award at 2026 Who is Who International Awards
  • Detained at 95: South Korea's Prosecution of a Religious Leader Draws International Alarm
  • CCHR: DOJ Takedown Exposes Over $220 Million Defrauded in Behavioral Mental Health Fraud Schemes
  • Exeter Smiles Encourages Reading Families to Start Teen Braces This Summer
  • ARC Technologies Announces Corporate Asset Sale of buildings, inventory and IP patents
  • Lady Liberty Is Coming Home: Historic WWII A-26 Invader Begins Her Final Journey to the Tulsa Air & Space Museum

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 290
  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
  • $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • What Would you Do with Your Time if it Was Actually Money?
  • Brilliant Minds to Gather in Fort Worth for National Mensa Event
  • West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
  • The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry

Similar on PennZone

  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us